SALKALLI- retatrutide lyophilized powder 5mg injection, powder, lyophilized, for solution

Guangzhou Yixin Cross-border E-commerce Co., Ltd.

Active ingredients (in each kit)

Retatrutide 5 mg (lyophilized powder)
Sterile Water for Injection 0.5 mL

Purpose

Antidiabetic / Weight management agent

Diluent

Uses

Helps control blood sugar in adults with type 2 diabetes (when prescribed). Intended to assist adults with weight loss as directed by a healthcare provider.

Warnings — Read carefully and tell your doctor if any apply to you.

Pancreatitis: Cases of pancreatitis have been reported. If you have severe abdominal pain (that may spread to the back), persistent vomiting, or signs of pancreatitis — stop using and contact your healthcare provider immediately.

Allergic reaction: Serious allergic reactions have been reported. Stop use and seek emergency care if you have hives, swelling of face/lips/tongue/throat, or trouble breathing.

Serious gastrointestinal disease: May cause GI adverse reactions. Not recommended for patients with severe GI disease (not studied).

Acute gallbladder disease: Cases (e.g., gallstones) have been reported. If you experience severe right-upper-abdominal pain or jaundice, seek medical evaluation.

Hypoglycemia warning: Do not use RETATRUTIDE if you have a history of recurrent or severe hypoglycemia. RETATRUTIDE may further lower blood glucose levels. Use is contraindicated in individuals with baseline hypoglycemia or conditions predisposing to hypoglycemia.

Pregnancy or breastfeeding: Do not use.

Children: Do not use.

Drug Interactions / Precautions

Other antidiabetic medications: Retatrutide lowers blood glucose. Using it with insulin or sulfonylureas may increase the risk of hypoglycemia. Blood glucose should be closely monitored; doses of other antidiabetic drugs may need adjustment.

Drugs affecting gastrointestinal motility: Retatrutide may delay gastric emptying. Coadministration with prokinetic agents (e.g., domperidone) or antacids may alter absorption or worsen GI discomfort. Cardiovascular medications: Caution with statins, digoxin, or warfarin.

Statins: absorption may be affected; monitor lipid levels.

Warfarin: changes in metabolism may alter anticoagulant effects; monitor INR levels.

General precautions: Retatrutide should be used only under medical supervision. Inform your healthcare provider about all medications, including prescription, over-the-counter, and herbal products.

Possible side effects

Nausea, diarrhea, decreased appetite, vomiting, constipation, dyspepsia (indigestion), abdominal pain. If side effects are severe or persistent, contact your healthcare provider.

When to stop and call your doctor

If you develop severe abdominal pain (possible pancreatitis), severe allergic reaction, jaundice, or other serious symptoms.

Directions — Preparation & Dosing (basic patient summary)

Concentration after reconstitution (calculation):

 $10 \text{ mg} \div 1 \text{ mL} = 10 \text{ mg/mL}.$

Therefore: 0.25 mL = 2.5 mg; 0.5 mL = 5 mg; 0.75 mL = 7.5 mg; 1 mL = 10 mg.

Typical weekly dosing schedule (example shown — follow your prescriber):

Weeks 1-4: 0.25 mL (2.5 mg) once weekly (subcutaneous)

Weeks 5-8: 0.5 mL (5 mg) once weekly

Weeks 9-12: 0.75 mL (7.5 mg) once weekly

Week 13 and onward: 1 mL (10 mg) once weekly

One carton (4 kits) provides 4 weekly doses.

How to prepare and inject (patient summary):

Wash hands with soap and water. Inspect vials for damage.

Using aseptic technique, withdraw the prescribed volume (in mL) of Sterile Water for Injection into a sterile syringe. Inject the diluent into the vial containing the lyophilized powder.

Gently swirl the vial until the powder fully dissolves. Do not shake vigorously. Solution should be clear; do not use if cloudy or particulate present.

Withdraw the prescribed volume (e.g., 0.25, 0.5, 0.75 or 1 mL) into a sterile syringe and inject subcutaneously in the abdomen, thigh, or upper arm after cleaning the site with alcohol. Rotate injection sites.

Dispose of syringe/needle in an appropriate sharps container.

Do not use

Other antidiabetic medications: Retatrutide lowers blood glucose. Using it with insulin or sulfonylureas may increase the risk of hypoglycemia. Blood glucose should be closely monitored; doses of other antidiabetic drugs may need adjustment.

Drugs affecting gastrointestinal motility: Retatrutide may delay gastric emptying. Co-

administration with prokinetic agents (e.g., domperidone) or antacids may alter absorption or worsen GI discomfort.

Cardiovascular medications: Caution with statins, digoxin, or warfarin.

Statins: absorption may be affected; monitor lipid levels.

Warfarin: changes in metabolism may alter anticoagulant effects; monitor INR levels.

General precautions: Retatrutide should be used only under medical supervision. Inform your healthcare provider about all medications, including prescription, over-the-counter, and herbal products.

When using section

Pancreatitis: Cases of pancreatitis have been reported. If you have severe abdominal pain (that may spread to the back), persistent vomiting, or signs of pancreatitis — stop using and contact your healthcare provider immediately.

Allergic reaction: Serious allergic reactions have been reported. Stop use and seek emergency care if you have hives, swelling of face/lips/tongue/throat, or trouble breathing.

Serious gastrointestinal disease: May cause GI adverse reactions. Not recommended for patients with severe GI disease (not studied).

Acute gallbladder disease: Cases (e.g., gallstones) have been reported. If you experience severe right-upper-abdominal pain or jaundice, seek medical evaluation.

Hypoglycemia warning: Do not use RETATRUTIDE if you have a history of recurrent or severe hypoglycemia. RETATRUTIDE may further lower blood glucose levels. Use is contraindicated in individuals with baseline hypoglycemia or conditions predisposing to hypoglycemia.

Pregnancy or breastfeeding: Do not use.

Children: Do not use.

Drug Interactions / Precautions

Other antidiabetic medications: Retatrutide lowers blood glucose. Using it with insulin or sulfonylureas may increase the risk of hypoglycemia. Blood glucose should be closely monitored; doses of other antidiabetic drugs may need adjustment.

Drugs affecting gastrointestinal motility: Retatrutide may delay gastric emptying. Coadministration with prokinetic agents (e.g., domperidone) or antacids may alter absorption or worsen GI discomfort.

Cardiovascular medications: Caution with statins, digoxin, or warfarin.

Statins: absorption may be affected; monitor lipid levels.

Warfarin: changes in metabolism may alter anticoagulant effects; monitor INR levels.

General precautions: Retatrutide should be used only under medical supervision. Inform your healthcare provider about all medications, including prescription, over-the-counter, and herbal products.

Possible side effects

Nausea, diarrhea, decreased appetite, vomiting, constipation, dyspepsia (indigestion), abdominal pain. If side effects are severe or persistent, contact your healthcare provider.

When to stop and call your doctor

If you develop severe abdominal pain (possible pancreatitis), severe allergic reaction, jaundice, or other serious symptoms.

stop use

Pancreatitis: Cases of pancreatitis have been reported. If you have severe abdominal pain (that may spread to the back), persistent vomiting, or signs of pancreatitis — stop using and contact your healthcare provider immediately.

Allergic reaction: Serious allergic reactions have been reported. Stop use and seek emergency care if you have hives, swelling of face/lips/tongue/throat, or trouble breathing.

Serious gastrointestinal disease: May cause GI adverse reactions. Not recommended for patients with severe GI disease (not studied).

Acute gallbladder disease: Cases (e.g., gallstones) have been reported. If you experience severe right-upper-abdominal pain or jaundice, seek medical evaluation.

Hypoglycemia warning: Do not use RETATRUTIDE if you have a history of recurrent or severe hypoglycemia. RETATRUTIDE may further lower blood glucose levels. Use is contraindicated in individuals with baseline hypoglycemia or conditions predisposing to hypoglycemia.

Pregnancy or breastfeeding: Do not use.

Children: Do not use.

Drug Interactions / Precautions

Other antidiabetic medications: Retatrutide lowers blood glucose. Using it with insulin or sulfonylureas may increase the risk of hypoglycemia. Blood glucose should be closely monitored; doses of other antidiabetic drugs may need adjustment.

Drugs affecting gastrointestinal motility: Retatrutide may delay gastric emptying. Coadministration with prokinetic agents (e.g., domperidone) or antacids may alter absorption or worsen GI discomfort.

Cardiovascular medications: Caution with statins, digoxin, or warfarin.

Statins: absorption may be affected; monitor lipid levels.

Warfarin: changes in metabolism may alter anticoagulant effects; monitor INR levels.

General precautions: Retatrutide should be used only under medical supervision. Inform your healthcare provider about all medications, including prescription, over-the-counter, and herbal products.

Possible side effects

Nausea, diarrhea, decreased appetite, vomiting, constipation, dyspepsia (indigestion), abdominal pain. If side effects are severe or persistent, contact your healthcare provider.

When to stop and call your doctor

If you develop severe abdominal pain (possible pancreatitis), severe allergic reaction, jaundice, or other serious symptoms.

Keep out of reach of children.


Not for use in children.

Inactive Ingredients:

Mannitol, Disodium Hydrogen Phosphate, Sodium Dihydrogen Phosphate, Sodium Chloride, Sodium Bicarbonate.

PRINCIPAL DISPLAY PANEL







Saikaiii

Retatrutide (lyophilized powder)

1 set containing 2 cartons (each carton contains 4 kits) 0.5ml: 5mg

0.5mL:

5_{mg}

Salkalli™ R



USA

Retatrutide (lyophilized powder)

1 set containing 2 cartons (each carton contains 4 kits)

For Reconstitution and Subcutaneous Use Only — Not for IV use Rx Only — Dispense only with prescription

Each kit provides a single weekly dose. One carton provides 4 weekly doses(4-week supply)

Salkalli™ Salkalli Retatrutide Sterile Water philized pow for Injectio

Each kit contains: Retatrutide 5 mg vial + Sterile Water for Injection 0.5 mL vial + sterile syringe

Store at room temperature below 25 °C (77 °F) before reconstitution. Excursions between 15 °C and 30 °C (59 °F and 86 °F) are permitted. After mixing, refrigerate at 2–8 °C (36–46 °F) and use within 24 hours per vial.

See enclosed leaflet for full instructions.



Solitable:

Company address line 1]

(Corry, State, Country)

Costomer Service: [phone] | [email] | [website]

Contents:

1 set containing 2 cartons,
each corton containing 4 complete single-use kits, each kit containing:
1 vial Retarturate 5 mg (keyphilized powder)
1 vial Retarturate 6 mg (keyphilized powder)
1 sterile syringe

Storage: Store unused kits at room temperature below 25 °C (77 °F). Excursions between 15 °C and 30 °C (59 °F and 86 °F) are permitted. After reconstitution, refrigerate of 2-8° ($^{\circ}$ 63-64 °F) and use within 24 hours. Protect from light and moisture. Do not freeze. Keep in original corton until use.

NDC: 00000-000-00. Rx Only. For prescription use only. Not for sale

0.5ml: 5mg

DRUG FACTS — For Patient Use (Prescription)

Active ingredients (in each kit)
Retatrutide 5 mg (lyophilized powder)
Sterile Water for Injection 0.5 mL.

Purpose Antidiabetic / Weight management agent Diluent

Uses

- Helps control blood sugar in adults with type 2 diabetes (when prescribed).
- Intended to assist adults with weight loss as directed by a healthcare provider.

Warnings — Read carefully and tell your doctor if any apply to you.

- Formandisco, color of Jones cells from the emporated. If you have severe discriminal poin of Pentrevellation. See a Jones cells from the emporated. If you have severe discriminal poin control your healthcare provided immediately.

 Allegic records: Assistant allegic records have been reported as 50 you and seek emergency care if you have helds, swelling of focallipathonguilathood, or trouble breathing. Serious gardenisted discoses Moy caused in other services. Not recommended for patients with severe of discose not studied.

 Acting patibodised delected. Ones list, position resident expected. If you experience server regiv super-discontrol pain is presented, peel medical evaluation. Center of the service of the server of t

- Children: Do not use. **Drug Interactions / Precurtions**Other omtidatest medications. Retrotuistic lowers blood glucose. Using it with insular or other omtidatest medications. Retrotuistic lowers blood glucose. Using it with insular or other omtidatest of hypoglycemia. Blood glucose should be closely monitored, doses of other ontidiobetic drugs may need odjustment. **Drugs affecting sostrainestation lawlity.** Retatuisties may belay gastric emptying.
 Co-daminatrollon with prohibited capits (e.g., domepaidoxe) or entocids may ditte absorption.
 Co-daminatrollon with prohibited capits (e.g., domepaidoxe) or entocids may dete absorption.
 O stories obsorption may be affected, monitor lipid levels.
 O Worldrin: Chapter in metabolism may ditte midrosogland effects, monitor file levels.
 O Worldrin: Chapter in metabolism may dite antidosogland effects, monitor file levels.
 The prohibited of the prohibited of the prohibited of the prohibited of the prohibited prohi

Possible side effects

When to stop and call your doctor

• If you develop severe abdominal pain (possible pancreatitis), severe allergic reaction, jaundice, or other serious symptoms.

Directions — Preparation & Dosing (basic patient summary)

Concentration after reconstitution (calculation):

• 10 mg + 1 mL = 10 mg/mL.

• Therefore: 0.25 mL = 2.5 mg; 0.5 mL = 5 mg; 0.75 mL = 7.5 mg; 1 mL = 10 mg.

Typical weekly dosing schedule (example shown — follow your prescriber):

- One cortion (4 kHz) provides 4 weekly doses.

 New to propore and inject (potient summary):

 1. Wosh hinneds with soop and water, inspect viols for damage.

 2. Wosh hinneds with soop and water, inspect viols for damage.

 2. Living agestic featuring, withdraw the prescribed violance (in mil., of Sterick Water for Injection

 2. Living agestic featuring, withdraw the prescribed violance (in mil., of Sterick Water for Injection

 3. Gently with the violance of the provider fully disaboles. Do not shock vigorously, Solution should

 5. Gently with the violance, Injection present.

 4. Withdraw the prescribed violance (e.g., 0.25, 0.5, 10.75 or 1 mil.) into a steelle syringe and inject

 5. Withdraw the prescribed violance (e.g., 0.25, 0.5, 10.75 or 1 mil.) into a steelle syringe and inject

 5. Dispose of syringe/ineedie in an appropriate sharps container.


Inactive Ingredients:
Mannitol, Disodium Hydrogen Phosphate, Sodium Dihydrogen Phosphate, Sodium Chloride,
Sodium Bicarbonate.

- Other information

 Store unused kits at tom temperature below 25 °C (77 °F). Excursions between 15 °C and 30 °C

 97 °G and 68 °P) are permitted. After reconstitution, refrigerate at 2-8°C (164-46 °P) and use width 27 shours. Protect from kight and moistate. Do not feetac. Resp. in original continual use. Proceedings of the control o





200mm

Salkalli™

Retatrutide (lyophilized powder)

1 set containing 3 cartons (each carton contains 4 kits) 0.5ml: 5mg

Salkalli™

USA

Retatrutide (lyophilized powder)

1 set containing 3 cartons (each carton contains 4 kits)

For Reconstitution and Subcutaneous Use Only — Not for IV use Rx Only — Dispense only with prescription

Each kit provides a single weekly dose. One carton provides 4 weekly doses(4-week supply)



0.5mL: 5_{mg}

Each kit contains: Retatrutide 5 mg vial + Sterile Water for Injection 0.5 mL vial + sterile syringe

Store at room temperature below 25 °C (77 °F) before reconstitution. Excursions between 15 °C and 30 °C (59 °F and 86 °F) are permitted. After mixing, refrigerate at 2–8 °C (36–46 °F) and use within 24 hours per vial.

See enclosed leaflet for full instructions.



Manufactured for: Salkalli™

Salkalli**
[Company address line 1]
[City, State, Country]
Customer Service: [phone] | [email] | [website]

- Customer Service: [phone] [[email]] [website]
 Contents:
 1 set containing 3 caratons,
 each carato containing 4 complete single-use kits, each kit containing:
 -1 vial Retutrutide 5 mg (lyophilized powder)
 -1 vial Sterile water for injection 0.5 mL
 -1 sterile syringe

Storage: Store unused kits at room temperature below 25 °C (77 °F). Excursions between 15 °C and 30 °C (59 °F and 86 °F) are permitted. After reconstitution, refrigerate at 2-8 °C (35-46 °F) and use within 24 hours. Protect from light and moisture. Do not freeze. Keep in original corton until use

NDC: 00000-000-00. Rx Only. For prescription use only. Not for sale without prescription.

0.5ml: 5mg

DRUG FACTS — For Patient Use (Prescription)

Purpose Antidiabetic / Weight management agent Diluent

Uses

• Helps control blood sugar in adults with type 2 diabetes (when prescribed),
• Intended to assist adults with weight loss as directed by a healthcare proving

- Intended to assist adults with weight loss as directed by a healthcare provider.

 **Warnings Read carefully and tell your doctor if any apply to you.

 **Pantereutitis: Costs of panceutitis have been regarded. If you have severe addominal pain and contact your healthcare provider immediately.

 **Allergic reaction: Serious aftering reactions have been reported. Stop use and seek emergency core if you have hives, swelling of facellipstronguithroat, or touble breathing.

 **Serious gasterinetism diseases: May couse of any evers encitors. Not recommended for potients with severe of ideases (not studied).

 **Acting plitableated deciseance: Seek sign, publishers have been reported. If you experience.

 **Allergic reaction: publishers and serious encitors and the properties of the publishers are all the properties of the publishers.

 **Applyperimitie warning. Do not use RETABUTIOE for printers have been globel seeks. Use is controllected in individuals with baseline hypophyremical serious controllected in Individuals with baseline hypophyremical controllected in Individuals with baseline hypophyremical controllected in Individuals with baseline hypophyremicals.

- **Chaldern to not use.

 Dray Interaction Precurition**

 **Other antidabetic medications Retarratise lowers blood glucose. Using it with insulin or authorized the medications retards the property of the state o

Possible side effects Nousen disease

When to stop and call your doctor

If you develop severe abdominal pain (possible pancreatitis), severe allergic reaction, jaundice, or other serious symptoms.

Directions — Preparation & Dosing (basic patient summary)

Concentration ofter reconstitution (calculation):

• 10 mg + 1 mL = 10 mg/mL.

• Therefore: 0.25 mL = 2.5 mg; 0.5 mL = 5 mg; 0.75 mL = 7.5 mg; 1 mL = 10 mg.

Typical weekly (soling schedul: (grouple shown — follow your prescriber): Weekes 1-4, 0.15 x (2m) go use seedly Weekes 5-6, 0.5 m (1.6 mg) go use seedly Weekes 5-6, 0.5 m (1.7 mg) go not seedly Weekes 5-7, 0.5 m (1.7 mg) go not seedly Weekes 5-7, 0.5 m (1.7 mg) go not go weekly Week 15 and powerd: 1 m (1.0 mg) go not weekly One carrion (4.8 th) provides 4 weekly doese.

- New York was go violent ** weekly violent **.

 **New to praper and inject (patient summary):

 1. Wosh hinds with soop and water. Inspect viole for damage.

 2. Using agestic textural, withdraw the prescribed volume (in mit,) of Sterile Water for Injection attors a self-in syringer. Bytec the observed in the wide containing the yophildrad provider. All to a self-in syringer self-in the observed in the self-in syringer self-in se

Inactive Ingredients:
Mannitol, Disodium Hydrogen Phosphate, Sodium Dihydrogen Phosphate, Sodium Chloride,
Sodium Bicarbonate.

- Other information

 Store unseed sits or come temperature below 25 °C (77 °F). Excursions between 15 °C and 30 °C
 (5°F ° and 56°F) are permitted. After reconstitution, refrigerate at 2-6°C (5-4-6°F) and use
 (50°F) and 56°F) are permitted. After reconstitution, refrigerate at 2-6°C (5-4-6°F) and use
 (50°F) are in the single-use. Discard any unused solution.

 Keep out of reconstrict of children.

 For questions, contact. Solution! Customer Care: [phone / email / website insert). To report
 side effects, cally our healthcase provider.

5mg冻干减肥注射器-4件套封套 尺寸:200 x 127 x 162 mm 工艺:350g白卡过光膜,四色印



200mm

Salkalli™

Retatrutide (lyophilized powder)

1 set containing 4 cartons (each carton contains 4 kits)

0.5ml: 5mg

Salkalli[™] ^R_x



USA

Retatrutide (lyophilized powder)

1 set containing 4 cartons (each carton contains 4 kits)

For Reconstitution and Subcutaneous Use Only — Not for IV use **Rx Only** — Dispense only with prescription

Each kit provides a single weekly dose. One carton provides 4 weekly doses(4-week supply)

Salkalli™ Salkalli Retatrutide Sterile Water philized pow for Injectio 0.5mL: 5_{mg}

Each kit contains: Retatrutide 5 mg vial + Sterile Water for Injection 0.5 mL vial + sterile syringe

Store at room temperature below 25 °C (77 °F) before reconstitution. Excursions between 15 °C and 30 °C (59 °F and 86 °F) are permitted. After mixing, refrigerate at 2–8 °C (36–46 °F) and use within 24 hours per vial.

See enclosed leaflet for full instructions.



Manufactured for:
Salkalli*
[Company address line 1]
[City, State, Country]
Customer Service: [plone] | [email] | [website]
Contents:
1 set containing 4 carrons,
each corton containing 4 complete single-use kits, each kit containing:
1 vial Returturble 5 mg (lyophilized powder)
1 vial Stefle Water for injection 0.5 mL
1 stefle Synrage

Storage: Store unused kits at room temperature below 25 °C (77 °F). Excursions between 15 °C and 30 °C (59 °F and 86 °F) are permitted. After reconstitution, refrigerate at 2-8 °C (36-46 °F) and use within 24 hours. Protect from light and moisture. Do not freeze. Keep in original corton until use

NDC: 00000-000-00. Rx Only. For prescription use only. Not for sale without prescription.

0.5ml: 5mg

ORUG FACTS — For Patient Use (Prescription)	 Nausea, diarrhea, decreased appetite, vomitting, constipation, dyspepsia (indigestion), abdominal pain. If side effects are severe or persistent, contact your healthcare provider. 		
ctive ingredients (in each kit) Purpose statrutide 5 mg (lyophilized powder) Antidiabetic / Weight management agent	When to stop and call your doctor If you develop severe obdominal pain (possible pancreatitis), severe allergic reaction, joundice, or other serious symptoms.		
erile Water for Injection 0.5 mL Diluent	Directions — Preparation & Dosing (basic patient summary)		
ses* Helps control blood sugar in adults with type 2 diabetes (when prescribed). Intended to assist adults with weight loss as directed by a healthcare provider.	Concentration after reconstitution (calculation): • 10 mg + 1mL = 10 mg/mL. • Therefore: 0.25 mL = 2.5 mg; 0.5 mL = 5 mg; 0.75 mL = 7.5 mg; 1 mL = 10 mg.		
Warnings — Read carefully and tell your doctor if any apply to you. Proceeditis: Cases of passecentitis have been reported: if you have severe obdominal pain control your been severe obdominal pain control your before profession and control your before profession and control your before profession and profession and the profession and profession an	Typical weekly dosing schedule (example shown — follow your prescriber): - Weeks 1-4 0.5 in, (LS mg) once weekly (subcutaneous) - Weeks 2-9 2.0 o 5 m, (LS mg) once weekly - Weeks 3-0 2.0 o 5 m, (LS mg) once weekly - Weeks 15 and onward: 1 ml. (D mg) once weekly - Onc catron (a kits) provided 4 weekly doses.		
Serious pastraintestiand diseases May couse (I adverse reactions, Not recommended for posterist with severe of disease (not studied on the contract of the contract of the Acute gaillatoder diseases. Close (e.g., gallatones) have been experience for the contract of the contract of the contract of the contract of the hypophycenia worming. Do not use RETAINUTE for you have on being or for extract or severe hypophycenia. RETAINUTE may further lower blood glucose levels. Use is contraindicated in individuals with bosterie hypophycenia or conditions predisposing to hypophycenia. Pregnancy or breast feeding. Do not use.	How to prepare and inject (potient usumery): 1. Wosh homes with soop and water. Inspect viola for damage. 2. Using caepic technique, withdraw the prescribed volume (nm.t) of Sterle Worter for injection into a sterle sympe, linject in disuns in the industrial time that containing the hyphilized powder. 3. Genthy swift the vol until the powder fully disobles. Do not shoke vigorously, Solution should be deep, or not use in flouchy or particulate present or I mill, lina or latelle sympe and inject in the substance of the present of the proposed injection should be considered to the proposed t		
Drug Interactions / Precautions Other antidiabetic medications: Retatrutide lowers blood glucose. Using it with insulin or sulfonylureas may increase the risk of hypoglycemia. Blood glucose should be closely monitored; doses of other antidabetic drugs may need adjustment.	Dispose of syringe/needle in an appropriate sharps container. Inactive Ingredients: Mannital, Disodium Hydrogen Phosphate, Sodium Dihydrogen Phosphate, Sodium Chloride, Sodium Bicarbonate.		
Drugs offecting gastrointestinal motility interduction may delay gastric emplying. Co-administroin with proderlised quest te gi, otherpeleobre of centrolised may defer discorption. Conditionscaled medications: Coultien with statins, disposit, or worfarin. O admiss discorption may be affected, morthor ligible evels. O admiss discorption may be affected, morthor ligible evels. Ocastric discorption may be affected, morthor ligible evels. General precountiens: Retartuistic thould be used only under medical supervision, Inform your healthcare provider about all medications, including prescription, over-the-counter, and herbal products.	Other information - Store unused itsis on memperature below 25 °C (77 °F). Excursions between 15 °C and 30 °C (97 °F). Excursions between 15 °C and 30 °C (97 °F). Excursions between 15 °C and 30 °C (97 °F). The store of 50 °C (97 °F) and use the store of 50 °C (97 °F). The store of 50 °C (97 °F) and use Each bit is single-use. Discord any unused scholars. - Keep out of reach of children. - For questions, contact: Sakallin' Customer Care: [phone Armold website — insert]. To report side effects, call your healthcare provider.		

SALKALLI

retatrutide lyophilized powder 5mg injection, powder, lyophilized, for solution

Product Information				
Product Type	HUMAN PRESCRIPTION DRUG	Item Code (Source)	NDC:84778-113	
Route of Administration	SUBCUTANEOUS			

Active Ingredient/Active Moiety			
Ingredient Name	Basis of Strength	Strength	
RETATRUTIDE (UNII: NOP2Y096GV) (RETATRUTIDE - UNII:NOP2Y096GV)	RETATRUTIDE	5 mg in 0.5 mL	

Inactive Ingredients			
Ingredient Name	Strength		
SODIUM BICARBONATE (UNII: 8MDF5V39QO)			
MANNITOL (UNII: 30WL53L36A)			
SODIUM PHOSPHATE, MONOBASIC, UNSPECIFIED FORM (UNII: 3980JIH2SW)			
SODIUM PHOSPHATE, DIBASIC, ANHYDROUS (UNII: 22ADO53M6F)			

SODIUM CHLORIDE (UNII: 451W47IQ8X)

Packaging				
#	Item Code	Package Description	Marketing Start Date	Marketing End Date
1	NDC:84778-113- 02	2 in 1 PACKAGE, COMBINATION	10/30/2025	
1		4 in 1 CARTON		
1		0.5 mL in 1 KIT; Type 1: Convenience Kit of Co-Package		
2	NDC:84778-113- 01	4 in 1 CARTON	10/30/2025	
2		0.5 mL in 1 KIT; Type 1: Convenience Kit of Co-Package		
3	NDC:84778-113- 03	3 in 1 PACKAGE, COMBINATION	10/30/2025	
3		4 in 1 CARTON		
3		0.5 mL in 1 KIT; Type 1: Convenience Kit of Co-Package		
4	NDC:84778-113- 04	4 in 1 PACKAGE, COMBINATION	10/30/2025	
4		4 in 1 CARTON		
4		0.5 mL in 1 KIT; Type 1: Convenience Kit of Co-Package		

Marketing Information			
Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
Export only		10/30/2025	

Labeler - Guangzhou Yixin Cross-border E-commerce Co., Ltd. (455800881)

Registrant - Guangzhou Yixin Cross-border E-commerce Co., Ltd. (455800881)

Establishment				
Name	Address	ID/FEI	Business Operations	
Guangzhou Yixin Cross-border E-commerce Co., Ltd.		455800881	label(84778-113) , manufacture(84778- 113)	

Revised: 11/2025 Guangzhou Yixin Cross-border E-commerce Co., Ltd.